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Background: Information on human papillomavirus (HPV) type distribution is necessary to evaluate the potential
impact of current and future HPV vaccines. We estimated the relative contribution (RC) to invasive cervical cancer
(ICC) and precancerous cervical lesions of the nine HPV types (HPV 6/11/16/18/31/33/45/52/58) included in an HPV
vaccine currently under development.
Methods: Estimations on ICC were based on an international study of 8,977 HPV positive cases and estimations on
precancerous cervical lesions were extracted from a published meta-analysis including 115,789 HPV positive
women. Globocan 2008 and 2010 World Population Prospects were used to estimate current and future projections
of new ICC cases.
Results: RC of the 9 HPV types in ICC was 89.4%, with 18.5% of cases positive for HPV 31/33/45/52/58. Regional
variations were observed. RCs varied by histology, ranging between 89.1% in squamous cell carcinomas (SCC) and
95.5% in adenocarcinomas (ADC). HPV 16/18/45 were detected in 94.2% of ADC. RC of the 9 types altogether
decreased with age (trend test p < 0.0001), driven by the decrease in older ages of HPV 16/18/45. In contrast, the
RC of HPV 31/33/52/58 increased with age. Due to population growth alone, projected estimates of ICC cases
attributable to the 9 types are expected to rise from 493,770 new cases in 2012 to 560,887 new cases in 2025.
The RCs of individual high risk HPV types varied by cytological and histological grades of HPV-positive precancerous
cervical lesions, and there was an under representation of HPV 18 and 45 compared to ICC.
Conclusions: The addition of HPV 31/33/45/52/58 to HPV types included in current vaccines could prevent almost
90% of ICC cases worldwide. If the nine-valent vaccine achieves the same degree of efficacy than previous vaccines,
world incidence rates could be substantially reduced.
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Cervical cancer and other HPV related cancers represent
an important global public health problem, both in more
and less developed countries. Cervical cancer is the third
most common cancer among women worldwide, with
an estimated 530,000 new cases and 275,000 new deaths
in 2008. More than 85% of the global cervical cancer
burden occurs in developing countries and in 12 of the* Correspondence: s.sanjose@iconcologia.net
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reproduction in any medium, provided the or22 regions of the world, cervical cancer remains the first
or second most common female cancer [1].
HPV carcinogenicity has been convincingly established
for cervical cancer and it is generally accepted that HPV
infection is necessary for the development of invasive
cervical cancer (ICC) [2]. The International Agency for
Research on Cancer (IARC) has classified HPV 16 and
18 as cervical carcinogens since 1995. By 2011 the group
was expanded to include HPV 31/33/35/39/45/51/52/
56/58/59 [3]. It is estimated that over 50-80% of sexually
active women will be infected with one or more genital
HPV types during their lives, with peak prevalence in
young sexually active individuals [3-5].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Serrano et al. Infectious Agents and Cancer 2012, 7:38 Page 2 of 13
http://www.infectagentscancer.com/content/7/1/38HPV prophylactic vaccines using virus like particles
(VLP) have been recognized as a major advance and the
most effective intervention to control for HPV and
cervical cancer [4]. Current licensed HPV vaccines, a
bivalent (CervarixTM) and a quadrivalent HPV vaccine
(GardasilW) are designed to prevent HPV infection and
HPV-related disease. CervarixTM was designed to pre-
vent infection by HPV types 16/18, which cause about
70 percent of cervical cancer cases [6,7], and GardasilW
targets the same two cancer causing types and, in
addition, is intended to prevent infection by HPV 6/11,
which cause close to 90% of external genital wart cases
[8]. These vaccines are near 100% effective in stimulating
the immune system against the strains targeted in the
vaccine when administered in a 3 dose course [9]. Given
the high safety and efficacy of both vaccines, many
countries have licensed and some have already included
them in their national immunization programs, but they
are yet to reach women in most low-income countries
[10]. In addition, the GAVI Alliance has announced
country applications for national introduction of HPV at
very low price aiming feasibility and sustainability of
such vaccines even in the very poor settings [11,12].
Future impact of HPV vaccination with current com-
mercialized vaccines has been largely modelled [13,14].
Models predict a substantial reduction in prevalence of
specific HPV 16/18 infections, followed by a reduction
in cervical abnormalities and a final reduction in ICC, if
coverage is high (>70%) and vaccine induced protection
lasts for at least 10 years [4]. The greatest impact is
expected in low-income and middle-income countries
where there is no screening or only limited screening for
cervical cancer and where the highest burden of cervical
disease is generally observed [4]. Impact of vaccination
with current HPV vaccines in low resource settings,
without any other preventive actions, is estimated to
potentially reduce cancer risk by 40–50% at 70% vacci-
nation coverage, with a potential reduction in the next
decade of more than 4 million deaths among vaccinated
women [14,15].
After HPV 16/18, data confirm HPV 31/33/35/45/52/
58 as the most frequently detected types in ICC world-
wide [6,7]. Merck is developing a recombinant nine-
valent vaccine, code named V503, that also uses virus
like particles (VLP). V503 contains 5 additional HPV
types (31/33/45/52/58) to the 4 HPV types previously
included in GardasilW and has successfully completed
several studies. Phase III studies are ongoing [16].
The aim of the present article is to estimate the poten-
tial impact of a new nine-valent vaccine in HPV-related
cervical disease by summarizing the evidence on specific
relative contribution (RC) of the 9 HPV types (HPV 6/
11/16/18/31/33/45/52/58) in ICC and precancerous
cervical lesions, in the pre-vaccination era.Methods
To estimate the RC of the 9 HPV types included in the
V503 Merck's investigational HPV vaccine, we used data
from an international study on HPV in ICC [7] and the
most recent meta-analysis in precancerous cervical
lesions available in the literature [17].
Cervical cancer
The estimations on RC in ICC were based on data from a
retrospective cross-sectional study carried out at Catalan
Institute of Oncology, Spain (ICO) in collaboration with
DDL laboratory, The Netherlands, to estimate the distribu-
tion of HPV types in women with ICC between 1949 and
2009 [7]. Briefly, the study included information from
10,575 ICC cases, and 8,977 (85%) of them were positive
for HPV DNA. Paraffin-embedded specimens from con-
secutive cases (aged 16–97 years) with ICC were
obtained from hospital pathology archives in 38 coun-
tries—Europe (Bosnia-Herzegovina, Croatia, Czech
Republic, France, Greece, Italy, Netherlands, Poland,
Portugal, and Spain); North America (USA); Central
and South America (Argentina, Brazil, Chile, Colombia,
Guatemala, Honduras, Mexico, Paraguay, Peru, and
Venezuela); Africa (Algeria, Mozambique, Nigeria, and
Uganda); Asia (Bangladesh, China, India, Israel, Japan,
South Korea, Kuwait, Lebanon, Philippines, Taiwan,
Thailand, and Turkey); and Oceania (Australia). After
the blocks were processed, inclusion criteria were a patho-
logical confirmation of a primary ICC of epithelial origin in
the tissue sample selected for analysis of HPV DNA. HPV
DNA detection was done by PCR with SPF-10 broad-
spectrum primers followed by DNA enzyme immunoassay
and genotyping with a reverse hybridization line probe
assay - LiPA25 that detects 25 high-risk (HR) and low-risk
(LR) HPV types (6/11/16/18/31/33/34/35/39/40/42/43/44/
45/51/52/53/54/56/58/59/66/68/70/74). Sequence analysis
was done to characterize HPV-positive samples with
unknown HPV types. If no HPV type could be attributed
after DNA sequencing, the HPV was labelled HPV
undetermined (52 cases out of 8,977 (0.6 %)). All protocols
were approved by the local and ICO ethics committees,
and the entire study progress was overseen by an inter-
national steering committee.
RC of the 9 HPV types included in the nine-valent
vaccine (HPV 6/11/16/18/31/33/45/52/58) in ICC was
expressed as the proportion of women positive for a
given type among all the HPV-positive samples. The
availability of HPV-disaggregated data made possible the
calculation of RCs for HPV types alone or for the groups
of HPV types. Multiple infections were added to single
types in accordance with a proportional weighting attri-
bution [18,19]. For example, if two ICC lesions found to
test positive for both HPV 16 and 45 in a region of the
world, and there were 9 cases infected by HPV-16 as a
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type, then [2*9/(9 + 1)] or 1.8 of these two multi-type
infected lesions would be attributed to HPV 16 and
[2*1/(9 + 1)] or 0.2 attributed to HPV 45.
Subjects were classified into 10 geographical regions
defined by the United Nations Population Divisions
(Africa, Asia, Eastern Asia, Western/Central Asia, Europe,
North America, Latin America, Central America, South
America and Oceania). RC was provided for the following
histological categories: Squamous Cell Carcinoma (SCC),
Adenocarcinoma (ADC), Adenosquamous Cell Carcinoma
(ADSCC) and Other histology that included undifferen-
tiated, neuroendocrine, not otherwise specified, basal ade-
noid and cystic adenoid carcinomas. Estimations of HPV
RCs by age groups were also provided. Evaluations of the
trends by age were determined by trend test analysis.
Statistically significant p-value for this analysis was set at
0.05 level.
Projections of new ICC cases attributed to HPV 16/18
and HPV 31/33/45/52/58 were calculated for year 2012
and projected to year 2025, worldwide and by region. Esti-
mations were based on the following assumptions and
data sources: a) Oncogenic HPV types may be detected in
virtually all cases of cervical cancer, being generally
accepted that the virus is necessary for the development
of cancer, so the RC of all HPV types altogether is
assumed to be 100%. Therefore, we assumed that the attri-
butional fraction (AF) for each HPV type in ICC corre-
sponded to the RC in ICC. The overall RC was used as
the world AF, without weighting regional estimations;
b) Globocan 2008 incidence rates were used with the
assumption that these rates will apply in the future [1];
c) We used the appropriate population forecast available
in the latest World Population Prospects (revision 2010)
[20]. Impact of vaccination was not taken into account.
Precancerous cervical lesions
The estimations on RCs in precancerous cervical lesions
were based on data from a recent IARC meta-analysis
[17]. Briefly, this meta-analysis included information on
HPV type distribution in 115,789 HPV-positive women
from 423 PCR-based studies worldwide. Inclusion cri-
teria were use of broad-spectrum consensus PCR-assays
based on the primers MY09/11, PGMY09/11, GP5+/6+,
SPF10, SPF1/GP6 or L1C1/L1C2, and information of
overall and type-specific HPV prevalence, by strata of
cyto- and/or histo-pathological cervical diagnoses. LR
HPV types were not included in the meta-analysis, so
specific information for HPV 6 and 11 was not provided.
Data were extracted from the manuscript for 12,983
cases (52% of which were HPV-positive) of atypical
squamous cells of undetermined significance (ASCUS),
17,805 cases (76% HPV-positive) of low-grade squamous
intraepithelial lesions (LSIL), and 7,743 cases (85% HPV-positive) of high-grade SIL (HSIL) diagnosed cytologically,
11,043 cases (73% HPV-positive) of cervical intraepithelial
neoplasia grade 1 (CIN1), 4,754 cases (86% HPV-positive)
of CIN2 and 11,618 cases (93% HPV-positive) of CIN3
diagnosed histologically. As described in the manuscript
[17], in order to retain appropriate sample size for com-
parisons between regions, precancerous cervical lesions
were collapsed in two categories; Low-grade, encompas-
sing ASCUS, LSIL and CIN1; and High-grade, including
HSIL, CIN2 and CIN3.
The RCs of the 7 individual HR HPV types (16/18/31/
33/45/52/58) were expressed as the proportion of samples
positive for a given type among all the HPV-positive sam-
ples tested for the mentioned type, therefore denomina-
tors vary by type. Individual-level data on HPV types in
multiple infections were not available, so RC includes
single and multiple infections and the total sum of RCs of
the 7 HR HPV can exceed 100%. Subjects were classified
into seven geographical regions defined by the United
Nations Population Divisions (Africa, Eastern Asia,
Western/Central Asia, Europe, North America, South/
Central America and Oceania) [17].
In an attempt to estimate a combined RC estimation
of the 7 HR HPV types altogether for CIN2/3 or HSIL
lesions similar to that in ICC, we used Smith et al. meta-
analysis [21] (for studies published from 2002 to 2006)
and Guan et al. meta-analysis [17] (for studies from
2006–2011) as data sources to identity papers providing
detailed data for single and multiple infections. We
established the following criteria for eligibility: (i) inclusion
of at least 75 cases of HSIL, CIN2 or CIN3, (ii) use of
broad-spectrum PCR, and (iii) reporting of type-specific
HPV prevalence for at least the 7 HR HPV genotypes
(HPV 16/18/31/33/45/52/58) included in the nine-valent
Merck’s vaccine. Forty seven studies met inclusion criteria,
including a total of 14,039 cases with an overall HPV
prevalence of 89.7%. Assessment of the RC of the 7 HR
HPV types altogether was only possible in 13 studies
(including 4,101 cases) where individual-level data on
HPV types in multiple infections was available.
Results
Cervical cancer
Combined RC of the 9 HPV types included in the nine-
valent vaccine (HPV 16/18/31/33/45/52/58/6/11) world-
wide was 89.4% (95%CI: 88.8-90.1), with some regional
variations, from 84.6% (95%CI: 81.9-87.1) in Central
America to 95.5% (95%CI: 91.2-98.2) in North America.
HPV 16/18 were the most common types accounting for
almost 70% worldwide, except for Central America and
North America where a RC of 64.4% (95%CI: 60.9-67.8)
and 78.8% (95%CI: 71.6-84.8) were observed respectively.
The additional RC of the other 5 high risk HPV types
(HPV 31/33/45/52/58) was 18.5% (95%CI: 17.7-19.3);
able 1 Relative contribution of HPV 16/18/31/33/45/52/58 in cases of ICC HPV-positive, by region



































































































































































1 3.7 (3.3-4.1) 1.9 (0.9-3.4) 3.0 (2.4-3.8) 2.8 (1.6-4.0) 3.2 (2.4-4.1) 4.9
(4.2-5.7)
6.5 (5.6-7.6) 4.3 (3.0-5 3.4 (1.0-7.1) 3.4 (2.7-4.3) 0.7 (0.0-3.2)
3 3.8 (3.4-4.3) 1.5 (0.6-2.9) 3.5 (2.8-4.3) 2.5 (1.6-3.8) 4.0 (3.1-4.9) 3.5
(3.2-4.5)
5.0 (4.3-6.0) 2.9 (1.9-4 3.1 (1.0-7.1) 5.7 (4.7-6.8) 2.1 (0.4-5.1)
5 5.9 (5.4-6.4) 9.9
(7.6-12.8)
5.5 (4.7-6.5) 7.0 (5.4-9.0) 4.9 (3.9-6.0) 6.8
(5.9-7.7)
3.7 (3.0-4.4) 7.5 (5.7-9 5.4
(2.6-10.4)
3.9 (3.1-4.8) 5.5 (2.5-9.8)
2 2.8 (2.5-3.2) 2.6 (1.4-4.3) 3.8 (3.1-4.6) 0.8 (0.3-1.7) 5.3 (4.3-6.4) 2.7
(2.2-3.3)
3.0 (2.4-3.7) 1.6 (0.9-2 2.9 (1.0-7.1) 1.9 (1.4-2.6) 0.6 (0.0-3.2)
8 2.3 (2.0-2.6) 0.7 (0.2-1.9) 3.9 (3.2-4.7) 1.3 (0.7-2.3) 5.0 (4.1-6.2) 2.0
(3.3-2.5)
1.4 (1.0-2.0) 3.9 (2.6-5 1.9
(0.39-5.4)
1.3 (0.9-1.9) 0.0 (0.0-2.2)
0.1 (0.1-0.2) 0.0 (0.0-0.7) 0.0 (0.0-0.2) 0.0 (0.0-0.4) 0.1 (0.0-0.3) 0.1 (0.0-0.3) 0.1 (0.0-0.3) 0.0 (0.0-0 0.0 (0.0-2.3) 0.2 (0.0-0.4) 1.8 (0.4-5.1)
1 0.0 (0.0-0.1) 0.0 (0.0-0.7) 0.0 (0.0-0.2) 0.0 (0.0-0.4) 0.1 (0.0-0.3) 0.0 (0.0-0.2) 0.0 (0.0-0.2) 0.0 (0.0-0 0.0 (0.0-2.3) 0.0 (0.0-0.2) 0.0 (0.0-2.2)
"ICC": Invasive cervical cancer; “RC”: Relative Contribution; “95%CI”: 95% Confidence Interval; * ”9 HPV types” includes the ones in nine-valent vaccine: HPV 16/18 1/33/45/52/58/6/11.
dditional information: Available data are from unvaccinated women (pre-vaccination period).
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http://www.infectagentscancer.com/content/7/1/38ranging from 8.8% (95%CI: 5.0-14.1) in Oceania to 22.3%
(95%CI: 20.4-24.3) in Eastern Asia. HPV 45 was the most
frequently detected type after HPV 16 and 18 worldwide
except in Eastern Asia where RCs of HPV 52/58 were
higher, and in Europe where RC of HPV 33 was higher. RC
of HPV 45 was especially prominent in Africa (9.9%; 95%
CI: 7.6-12.8), Western Asia (7.0%; 95%CI: 5.4-9.0) and
Latin-America (6.8%; 95%CI: 5.9-7.7). HPV 31 was
relatively more prevalent in Latin-America (4.9%; 95%CI:
4.2-5.7) and HPV 33 was more prevalent in Europe (5.7%;
95%CI: 4.7-6.8), as previously remarked. Infections by HPV
52/58 were more usually diagnosed in Eastern Asia (5.3%;
95%CI: 4.3-6.4 and 5.0%; 95%CI: 4.1-6.2, respectively).
Addition of HPV 6/11 did not modify the cancer burden
estimates (RC: 0.1%) (Table 1).
Regarding histological diagnosis, the combined RC of
the 9 HPV types ranged from 89.1% (95%CI: 88.4-89.7)
in SCC to 95.5% (95%CI: 93.3-97.2) in ADC. HPV 16/
18/45 were consistently the three most common types in
all histological categories accounting for 94.2% (95%CI:
91.7-96.2) of ADC cases compared to the 75.4% (95%CI:
74.5-76.3) contribution in SCC. A greater contribution
of HPV 18/45 was observed in ADC, ADSCC and other
histologies compared to that in SCC and conversely,
HPV 16 RC was higher in SCC. Substantial differences
in the RCs by histological category were observed for
the other HPV types, with much higher contributions of
HPV 31/33/52/58 in SCC (RC: 13.6%) and ADSCC (RC:
7.2%) compared to the RC of less than 1% and 3%
observed in ADC cases and other histologies, respec-
tively (Figure 1).
The RC of the 9 types altogether decreased with age




















ADC (470) ADSCC (155) SCC (8,252)
Figure 1 Relative contribution of HPV 16/18/31/33/45/52/58 in cases
“SCC”: Squamous cell carcinoma; “ADC”: Adenocarcinoma; “ADSCC”: Adeno
neuroendocrine, not otherwise specified, basal adenoid and cystic adenoid
unvaccinated women (pre-vaccination period). Type specific relative contrib
attribution of multiple types; Denominator = HPV DNA positive cervical can
Specific information on HPV 6 and 11 is not included due to the low relatiby the decrease in older ages of HPV 16/18/45. In con-
trast, ICC cases in women positive for HPV 31/33/52/58
increased with age (trend test p < 0.0001), although HPV
16/18/45 were also the most common types in older ages.
Remarkable differences were found in ICC cases positive
for HPV types other than those included in the nine-
valent vaccine, with RCs ranging from 4.2% (95%CI:
0.5-14.3) in women aged less than 25 years to 19.4% (95%
CI: 13.7-26.0) in women older than 80 years (Figure 2).
Without changes in prevention and control, and only
due to population growth, projections for the next years
reveal a growing burden of cervical cancer. Projected
global estimates of ICC cases, not taking into account
the impact of vaccination and assuming that all cases
are related to HPV infection, are expected to rise to
627,354 new cases in 2025, with 444,167 cases attri-
butable to HPV 16/18 and 116,061 cases attributable
to HPV 31/33/45/52/58. Over 60% of cases will come
from Asia, 16% from Africa and 13% from Latin
America (Table 2).
Precancerous cervical lesions
RCs of individual HR HPV types varied by cytological
and histological grade of HPV-positive precancerous cer-
vical lesions.
HPV 16 was the most frequently detected HR type in
every grade of cervical lesion. Its importance increased
with the severity of the lesion, with RCs of 47.5% (95%
CI: 46.3-48.7) in HPV-positive HSIL and 58.2% (95%CI:
57.3-59.1) in HPV-positive CIN3 diagnoses. HPV 45 was
consistently detected less often than other HR types
included in the nine-valent vaccine in all cytological and









of ICC HPV-positive, by histology. "ICC": Invasive cervical cancer;
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Figure 2 Relative contribution of HPV 16/18/45/31/33/52/58 and other types in ICC cases HPV-positive, by age group. "ICC": Invasive
cervical cancer; Additional information: Available data are from unvaccinated women (pre-vaccination period). Type specific relative contribution
estimations: Numerator = single infections + proportional attribution of multiple types; Denominator = HPV DNA positive cervical cancer cases.
The number of cases by age group is shown in “( )”. Specific information on HPV 6 and 11 is not included due to the low relative contribution of
these types.
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http://www.infectagentscancer.com/content/7/1/38Regional variations in the RCs of precancerous cervical
lesions due to each HR HPV type were also observed.
HPV 16 was the most common type in all regions in
both low-grade and high-grade lesions. RC in HPV-
positive high-grade lesions ranged from 30.3% to 60.3%.
HPV 45 was the less frequently detected HR type in the
majority of regions of the world (including Africa, where
we found it to be an important HPV type in ICC).
Regarding HPV-positive high-grade lesions, HPV 31 was
relatively more prevalent in Western and Central Asia,and similarly to that found in ICC; HPV 52/58 showed
higher RCs in Eastern Asia (Table 3).
In the review of published papers in order to assess
the RC of the 7 HR HPV types altogether for CIN2/3 or
HSIL lesions, extraction of detailed data of single and
multiple infections was possible in 4,101 cases (13 studies).
Similar to ICC lesions, multiple infections were added to
single types in accordance with a proportional weighting
attribution. Multiple infections were higher in included
studies compared to that in not included studies (41.3% vs
Table 2 Burden of ICC attributable to HPV 16/18 and HPV 31/33/45/52/58 in 2012, projected to 2025; by region
Region HPV RC (%) Attributable new cases (N)
16/18 31/33/45/ 52/58 Year 2012 Year 2025
16/18 31/33/45/ 52/58 16/18 31/33/45/52/58
World 70.8 18.6 391,016 102,172 444,167 116,061
Africa 70.3 16.7 60,925 14,438 80,556 19,090
Asia 71.7 19.8 232,046 63,986 259,130 71,454
Eastern Asia 68.9 22.3 95,505 30,869 100,950 32,629
Western/Central Asia 77.5 14.5 145,101 27,073 171,333 31,967
Latin-America 68.3 19.8 48,777 14,142 54,973 15,938
South America 69.4 19.6 34,632 9,799 38,783 10,973
Central America 64.4 20.2 13,602 4,264 15,522 4,866
North America 78.7 16.6 9,913 2,094 10,913 2,305
Europe 72.8 16.2 39,880 8,867 39,924 8,877
Oceania 78.5 8.8 1,346 152 1,587 179
* We assume that almost all cervical cancer cases are caused by HPV infection, and thus almost 100% of cervical cancer cases are attributable to HPV infection.
"ICC": Invasive cervical cancer; “RC”: Relative Contribution; “N”: Number of new cases diagnosed of cervical cancer each year.
Estimated number of new ICC cases is based on GLOBOCAN 2008 estimates and World Population Prospects (2010 revision). Impact of vaccination has not been
taken into account for the calculations of 2025 projections.
Specific information on HPV 6 and 11 is not included due to low relative contribution of these types.
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RC of the 9 HPV types observed in ICC, large variations
between articles were observed for CIN2/3 or HSIL lesions,
with RCs of the 7 HR HPV types ranging from 58.8% to
93.6%. Individual information on LR HPV 6/11 was avai-
lable in 10 studies. Addition of HPV 6/11 did not modify
the CIN2/3 or HSIL burden estimates (less than 1%).
Discussion
We provided information on HPV distribution of 9 types
included in a broad spectrum vaccine currently under
development for 10 regions of the world and across dif-
ferent grades of cervical lesions. Although existing vac-
cines cover HPV 16/18 that are responsible of 70% of
ICC worldwide, the inclusion of HR HPV 31/33/45/52/
58 would increase the protection to almost 90% of the
infections responsible for ICC.
As previously reported, HPV 16 is uniformly the most
common HPV type in all histological types of cervical
cancer and all the regions of the world [7,17]. Our find-
ings confirmed the regional variations in the RCs of ICC
due to each specific HPV type, with the most important
differences observed in Eastern Asia, where HPV 52/58
are identified in more than 10% of cases, and the higher
frequency of HPV 33 in Europe (6%), HPV 31 in South
America (7%) and HPV 45 in Africa (10%) [7,17,22,23].
RC estimations in Africa from ICC study reflect that
52% of ICC cases were infected with an HPV type diffe-
rent from HPV 16. The different RCs on HPV genotypes
in Africa are not fully understood. Different RCs may be
related to host genetic determinants or could be the result
of a different distribution on HPV types in HIV-infectedwomen compared to that of the general population
[24,25]. In Africa it should also be remarked the impor-
tance of HPV 35, identified in 5% of ICC cases in this
region and ranking as the fourth most frequent type after
HPV 16/18/45.
Our data confirm that HPV 16 is the most common
type in all cervical lesions. By contrast, HPV 18/45 are
underrepresented in HPV-positive women with precan-
cerous cervical lesions compared to the high contribu-
tion in ICC, where these types are consistently the
second and third most common types in most of the
world regions [6,7,17]. Recent published data in high
grade cervical lesions are in agreement with the reported
results from Guan et al. meta-analysis, and suggests the
representativeness of the study data [26].
It should be remarked that HPV 16/18/45 were
detected at younger ages in ICC compared to other HPV
types. Particularly for HPV 18/45, the detection at
younger ages together with the underrepresentation in
precancerous cervical lesions suggest a rapid progression
to ICC of both HPV types, with or without transition
through preinvasive stages [27,28].
Due to the restricted genotype contribution in the patho-
genesis of ADC subtype, higher rates of protection with the
vaccine could be expected, compared to SCC (95.5% vs
89.1%, respectively). Similar to previous findings a greater
contribution of HPV 18/45 in ADC, ADSCC, and other
histologies (such as neuroendocrine tumours) was observed
compared to that in SCC and conversely, HPV 16 RC was
higher in SCC [6,29-31]. Our data showed that HPV 16/18/
45 were responsible for more than 94% of ADC. Much
higher contributions of HPV 31/33/52/58 were observed in
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Figure 3 Relative contribution of HPV 16/18/45/31/33/52/58 in precancerous cervical lesions HPV-positive, by histological and
cytological diagnosis. “CIN1”: Cervical intraepithelial neoplasia grade 1; “CIN2”: Cervical intraepithelial neoplasia grade 2; “CIN3”: Cervical
intraepithelial neoplasia grade 3 (including squamous carcinoma in situ); “ASCUS”: Atypical squamous cells of undetermined significance; “LSIL”:
Low-grade squamous intraepithelial lesion; “HSIL”: High-grade squamous intraepithelial lesion; “RC”: Relative Contribution; “95%CI”: 95%
Confidence Interval. Additional information: HPV type specific relative contribution: Numerator = includes either single or multiple infections, thus
the total sum of % can exceed 100%; Denominator = ”Tested” cases that stands for the HPV/DNA positive cases from studies testing for the HPV
type in question, thus denominators vary by type. The data source does not give specific information for HPV 6 and 11. 17. Data from Guan et al.,
IJC, 2012.
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http://www.infectagentscancer.com/content/7/1/38SCC (RC: 13.6%) and ADSCC (RC: 7.2%) compared to the
RC of less than 1% observed in ADC cases. Only 4.5% of
ADC cases were due to HPV types not included in the
nine-valent vaccine. Therefore, this broad spectrum vaccine
could help to reduce the increasing rates of cervical ADC
reported in the last decades in some countries with estab-
lished screening programmes, which is in keeping with the
relative inability of cytological screening to reduce the rates
of invasive ADC [32-34].
The existence of multiple infections complicates the
estimation of the attribution of cases to HPV types.Assessment of RC of multiple infections was possible for
ICC lesions, where multiple infections were added to single
types in accordance with a proportional weighting attribu-
tion. We also calculated a more conservative RC by com-
bining single type infections and multiple type infections
restricted to the exact combination of the 9 mentioned
types obtaining a RC close to 86% worldwide, meaning that
the HPV types included in the nine-valent vaccine could
cover the majority of infections responsible of ICC.
No similar attribution of multiple infections could be
performed for precancerous cervical lesions from Guan




Low grade High grade
HPV-positive RC 95%CI HPV-positive RC 95%CI
Africa HPV-16 517 16.8 (13.7-20.3) 251 30.3 (24.7-36.4)
HPV-18 517 8.3 (6.1-11.0) 251 9.2 (5.9-13.4)
HPV-31 432 6.5 (4.4-9.2) 245 8.2 (5.0-12.3)
HPV-33 517 8.5 (6.3-11.3) 235 8.9 (5.6-13.3)
HPV-45 432 4.4 (2.7-6.8) 245 4.1 (2.0-7.4)
HPV-52 432 11.8 (8.9-15.2) 245 11.0 (7.4-15.6)
HPV-58 517 10.8 (8.3-13.8) 251 11.2 (7.5-15.7)
Eastern Asia HPV-16 2,790 21.1 (19.6-22.6) 3,693 37.9 (36.4-39.5)
HPV-18 2,790 8.3 (7.3-9.4) 3,693 7.4 (6.5-8.3)
HPV-31 2,552 4.4 (3.7-5.3) 3,596 6.9 (6.1-7.8)
HPV-33 2,790 5.0 (4.2-5.8) 3,693 9.9 (9.0-11.0)
HPV-45 2,549 1.2 (0.8-1.7) 3,148 2.0 (1.6-2.6)
HPV-52 2,624 18.2 (16.8-19.8) 3,469 21.3 (20.0-22.7)
HPV-58 2,781 13.5 (12.3-14.9) 3,647 19.6 (18.3-20.9)
Western/Central Asia HPV-16 237 30.8 (25.0-37.1) 79 68.4 (56.9-78.4)
HPV-18 237 6.8 (3.9-10.7) 79 6.3 (2.1-14.2)
HPV-31 229 4.4 (2.1-7.9) 63 23.8 (14.0-36.2)
HPV-33 210 7.1 (4.1-11.8) 31 9.7 (2.0-25.8)
HPV-45 189 2.1 (0.6-5.8) 28 7.1 (0.9-23.5)
HPV-52 72 2.8 (0.3-9.7) 20 0.0 (0.0-16.8)
HPV-58 189 6.4 (3.3-10.8) 28 10.7 (2.3-28.2)
South/Central America HPV-16 2,692 25.1 (23.5-26.8) 1,896 52.9 (50.6-55.1)
HPV-18 2,690 6.8 (5.9-7.9) 1,886 9.4 (8.2-10.9)
HPV-31 2,504 5.2 (4.4-6.1) 1,837 10.6 (9.2-12.1)
HPV-33 2,517 7.5 (6.5-8.6) 1,776 6.5 (5.3-7.7)
HPV-45 2,166 4.5 (3.7-5.5) 1,669 4.8 (3.8-5.9)
HPV-52 2,127 5.1 (4.2-6.1) 1,587 6.3 (5.2-7.6)
HPV-58 2,220 6.9 (5.8-8.0) 1,589 9.5 (8.1-11.1)
North America HPV-16 5,532 24.7 (23.6-25.6) 4,598 56.7 (55.3-58.2)
HPV-18 5,532 9.5 (8.7-10.3) 4,598 9.6 (8.8-10.5)
HPV-31 5,532 8.9 (8.1-9.6) 4,598 13.1 (12.1-14.1)
HPV-33 5,317 4.2 (3.7-4.8) 4,598 7.6 (6.9-8.4)
HPV-45 5,415 5.6 (5.0-6.2) 4,397 4.8 (4.2-5.5)
HPV-52 4,839 10.7 (9.9-11.6) 4,205 10.3 (9.4-11.3)
HPV-58 5,213 7.6 (6.9-8.3) 4,397 6.8 (6.1-7.6)
Europe HPV-16 14,319 25.9 (25.2-26.6) 8,348 54.4 (53.3-55.5)
HPV-18 14,256 9.1 (8.6-9.6) 8,214 7.7 (7.2-8.3)
HPV-31 13,166 12.5 (12.0-13.1) 7,930 12.4 (11.6-13.1)
HPV-33 13,186 6.6 (6.2-7.1) 7,844 9.4 (8.7-10.0)
HPV-45 10,472 4.6 (4.2-5.1) 6,244 3.8 (3.3-4.3)
HPV-52 9,577 8.3 (7.8-8.9) 6,067 7.2 (6.6-7.9)
HPV-58 10,489 6.7 (6.2-7.2) 6,278 5.8 (5.2-6.4)
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Table 3 HPV 16/18/31/33/45/52/58 type-specific relative contribution in precancerous cervical lesions HPV-positive,
by region (Continued)
Oceania HPV-16 385 24.7 (20.5-29.3) 924 53.9 (50.6-57.2)
HPV-18 385 8.6 (6.0-11.8) 924 9.6 (7.8-11.7)
HPV-31 385 13.3 (10.0-17.0) 924 12.3 (10.3-14.6)
HPV-33 385 5.7 (3.6-8.5) 924 7.9 (6.2-9.8)
HPV-45 385 6.5 (4.3-9.4) 924 4.2 (3.0-5.7)
HPV-52 385 11.4 (8.4-15.0) 924 12.2 (10.2-14.5)
HPV-58 385 9.1 (6.4-12.4) 924 5.8 (4.4-7.6)
Low-grade, includes ASCUS, LSIL and CIN1; High-grade, includes HSIL, CIN2 and CIN3.
“RC”: Relative Contribution; “95%CI”: 95% Confidence Interval.
Additional information: HPV type specific relative contribution: Numerator = includes either single or multiple infections, thus the total sum of % can exceed
100%; Denominator = ”Tested” cases that stands for the HPV/DNA positive cases from studies testing for the HPV type in question, thus denominators vary by
type.
The data source does not give specific information for HPV 6 and 11.
17. Data from Guan et al., IJC, 2012.
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http://www.infectagentscancer.com/content/7/1/38et al. meta-analysis, meaning that HPV positive women
with multiple infections could be counted more than
once. Hence RCs for precancerous lesions was shown
only for individual, and not combinations of HPV types.
Although this approach does not allow to estimate type
specific risk, it can be useful to identify HPV variations
by region or lesion severity, as it has been confirmed
that HPV type is the strongest factor that affects the
risks of progression of precancerous cervical lesions
given viral persistence, with HPV 16 and 18 less likely to
regress than other HPV types [34].
CIN2/3 lesions rarely occur in absence of HR HPV
infections [26,34,35], but this has not been confirmed in
lower grades of cervical lesions. Data from Guan et al.
meta-analysis reveal that only 52% of ASCUS cases were
positive for HPV DNA compared to the more than 85%
of positivity in CIN2/3 or HSIL lesions. We tried to
estimate the combined RC of the 7 HR HPV types
altogether for CIN2/3 or HSIL lesions similar to that in
ICC obtaining a wide range from 58.8% to 93.6%., but
due to the limitations of study designs, data should be
interpreted cautiously and further research is needed to
provide solid estimations taking into account attribution
of multiple infections.
For estimations of HPV attributable cases, we assumed
that current incidence rates will apply in the future, and
calculated expected numbers using the appropriate
population forecast. We did not take into account the
impact of screening programs and current vaccines that
will influence future rates since this type of analysis is
more suitable for more complex analysis such as simula-
tion models. Particularly for HPV vaccines it has to be
taken into consideration that vaccination programs are
not implemented worldwide, the coverage is still very
low (especially in low income countries) and the impact
on the reduction of invasive lesions will need more than
ten years to be observable. The overall RC was used as
the world AF. Even weighting regional estimations byworld populations, the world attributable number of
cases did not differ. Irrespective of changing risk, demo-
graphic changes will have a major impact in the future
burden of ICC and this will be especially remarkable in
developing countries where, in general incidence and
mortality rates have been relatively stable over decades,
reflecting the lack of screening implementation [32].
These estimates can help decision-makers evaluate the
potential impact of existing and future vaccines world-
wide providing an estimation of the proportion of HPV
related cancer that could be avoided if the populations
become immune to the 9 types of HPV included in the
vaccine.
The good concordance of HPV estimations with previ-
ous reports suggests the representativeness of the study
data, and especially in those regions with large sample
sizes. Eighty five percent of all ICC from the ICC study
were positive for DNA, compared to the ninety percent
estimated in the most recent IARC meta-analysis on
ICC available in the literature [6]. Given that HPV is
accepted as a necessary cause of ICC, the negativity of
both studies is expected to be related to technical rea-
sons, but also to the quality of the biological specimen.
The low number of cases in the ICC study from Oceania
and North America could be a potential limitation. Al-
though RCs for Oceania are similar to that observed in
previous reports, estimations of RCs for North America
based on this study differ to that observed in the IARC
meta-analysis and the largest study performed in this re-
gion by Wheeler et al. [6,36], with higher rates for HPV
16 (72% vs 55% and 53% respectively) and lower for HPV
18 (7% vs 18% and 13% respectively). RC for the other
HPV types included in the vaccine was similar between
studies. A possible explanation could be the different year
of diagnosis of the cases. Wheeler et al. observed that the
proportion of HPV 16 positive cases declined with more
recent calendar year of diagnosis. On the other hand, esti-
mates from the meta-analysis and Wheeler et al. study
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cases. In order to assess these differences we recalculated
estimations for North America using all tested women as
a denominator and although RC of HPV 16 decreased, it
was still higher in the included ICC study.
Irrespective of histological type and similar to previous
reports [37], HPV 16/18/45 were identified in younger
women more than other HPV types. Combined with the
low proportion of ICC cases attributable to HPV types
not included in the nine-valent broad spectrum vaccine,
it suggests that such intervention would imply a drastic
reduction of screening intervention in vaccinated cohorts.
Conclusions
The inclusion of additional HPV types in nine-valent
vaccine currently under development could have direct
implications for cervical cancer incidence and preven-
tion in all regions of the world. If the nine-valent vaccine
achieves the same degree of efficacy as has been shown
for HPV 16 and 18, and vaccination programs are effec-
tively implemented, almost the 90% of ICC cases world-
wide could be prevented. This means that Globocan
2008 world incidence rates could be substantially
reduced. If all our estimations are true, and assuming
high vaccination coverage and no HPV type replace-
ment, this intervention would provide a higher impact
than any screening programme has ever produced in the
very best scenarios.
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